ERBB2 and lung adenocarcinoma: Here, we highlighted a clinical female case of lung adenocarcinomas harboring HER2 exon 20 insertion mutations who experienced partial response to trastuzumab deruxtecan (DS-8201) after failure of chemotherapy, targeted therapy and immunotherapy.